Skip to main
DXCM

DexCom (DXCM) Stock Forecast & Price Target

DexCom (DXCM) Analyst Ratings

Based on 22 analyst ratings
Buy
Strong Buy 50%
Buy 36%
Hold 9%
Sell 5%
Strong Sell 0%

Bulls say

DexCom's stock outlook remains positive due to a notable increase in international revenue, which grew 22% year-over-year, indicating successful market penetration and recent coverage wins in key regions such as France and Canada. The company's domestic business also showed significant growth, achieving approximately $852 million in revenue, a 21% increase, driven by a strong influx of new customers from the Type 2 diabetes segment. Furthermore, DexCom raised its full-year sales guidance, now anticipating revenues between $4.630 billion and $4.650 billion, bolstered by long-term trends in remote monitoring, innovative pipeline developments, and a more accessible business model.

Bears say

DexCom is adjusting its profitability outlook downward, signaling potential challenges ahead as it anticipates a gross margin reduction to 61% due to rising scrap issues. The company failed to achieve a record number of new patients in Q3, a concerning trend that may reflect ongoing quality issues impacting business performance as competition intensifies. Additionally, a notable decrease in adjusted EBIT and EBITDA projections further highlights financial uncertainties, with forecasted year-over-year growth rates for 2026 and 2027 now lowered to approximately 12% and 13%, indicating a cautious outlook in a competitive market.

DexCom (DXCM) has been analyzed by 22 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 36% recommend Buy, 9% suggest Holding, 5% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of DexCom and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About DexCom (DXCM) Forecast

Analysts have given DexCom (DXCM) a Buy based on their latest research and market trends.

According to 22 analysts, DexCom (DXCM) has a Buy consensus rating as of Jan 13, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $86.41, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $86.41, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

DexCom (DXCM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.